Empagliflozin and linagliptin are currently in clinical development for type 2 diabetes mellitus (T2DM) in children and adolescents. T2DM is a lifelong condition that develops when the body becomes resistant to, or does not produce enough, insulin – a hormone produced in the pancreas. Insulin is needed for controlling the amount of sugar in the blood. A lack of insulin in T2DM patients causes blood sugar levels to become too high. If blood sugar remains high over a long period of time this can result in serious complications. However, medicinal options for children and adolescents with T2DM are limited at this time.
Empagliflozin with linagliptin for treating type 2 diabetes mellitus in children and adolescents
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Empagliflozin and linagliptin are currently in clinical development for type 2 diabetes mellitus (T2DM) in children and adolescents. T2DM is a lifelong condition that develops when the body becomes resistant to, or does not produce enough, insulin – a hormone produced in the pancreas.
Indications:
Type 2 diabetes
Therapeutic Areas:
Endocrine Nutritional and Metabolic Disorders
Year:
2022